The Role of Urinary N-acetyl-beta-glucosaminidase in Diagnosis of Kidney Diseases
Journal of Pediatric Nephrology,
Vol. 3 No. 3 (2015),
N-acetyl-beta-D-glucosaminidase (NAG) is a lysosomal enzyme present in the proximal convoluted tubules of the kidneys that may be used as a marker of proximal tubular damage and nephrotoxicity. An abnormal urinary NAG excretion has been reported in different kinds of renal disorders such as acute kidney injury, urinary tract infection, vesicoureteral reflux; diabetes mellitus; nephrotic syndrome; glomerulonephritis; hypertension; perinatal asphyxia; heavy metals poisoning; drug nephrotoxicity, renal allograft rejection; and heart failure. This paper provides an overview of the diagnostic value of urinary NAG in the nephrourology field.
Keywords: N-acetyl-beta-D-glucosaminidase; Acute Kidney Injury; Kidney Diseases; Pyelonephritis; Hypertension; Vesico-Ureteral Reflux.
How to Cite
Vanderlinde RE. Urinary enzyme measurements in the diagnosis of renal disorders. Ann Clin Lab Sci 1981; 11: 189-201.
Feldmann D, Flandrols C, Jardel A, MInhPhan T, Aymard P. Circadian Variations and Reference Intervals for Some Enzymes in Urine of Healthy Children. Clin. Chem 1989; 35(5):864-867.
Csáthy L, Oláh AV, Pócsi I, Varga J, Balla G, Price RG. Age-dependent urinary N-acetyl-beta-D-glucosaminidase activity in healthy children. Orv Hetil 1994;135(24):1301-1303.
Dejan Spasovski. Renal markers for assessment of renal tubular and Glomerular dysfunction. J Nephropharmacol 2013;2(2):23–25.
Liangos O, Perianayagam M. Urinay NAG activity and KIM-1 level are associated with adverse outcomes in acute renal failure. JASN 2007; 18: 904–912.
Price RG. Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications. European Journal of Clinical Chemistry and Clinical Biochemistry 1992;30(10):693-705.
Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;38:S14-9.
Skálová S. the diagnostic role of urinary n-acetyl-β β-d-glucosaminidase (NAG) activity in the detection of renal tubular impairment. ACTA MEDICA (Hradec Králové) 2005;48(2):75–80.
Matsushima H, Yoshida H, Machiguchi T et al. Urinary albumin and TGF 1 levels as renal damage indices in patients with congestive heart failure. Clin Exp Nephrol 2002; 6: 21–29.
Smets P M Y, Meyer E, Maddens BEJ, Duchateau L, Daminet S. Urinary Markers in Healthy Young and Aged Dogs and Dogs with Chronic Kidney Disease. J Vet InternMed 2010;24:65–72.
Nishida M, Kawakatsu H, Komatsu H, et al. Values for urinary β-microglobulin and N-acetyl-β-D-glucosaminidase in normal healthy infants. Pediatrics International 1998;40(5):424-6.
Neufeld EF. Natural history and inherited disorders of a lysosomal enzyme, beta hexosaminidase. J Biol Chem 1989; 264: 10927-30.
Robinson D, Stirling JL. N-Acetyl-beta-glucosaminidases in human spleen. Biochem J 1968; 107: 321-7.
Rodriguez-Cuartero A, Lopez-Fernandez A, Perez-Blanco F. Urinary N-acetyl-beta-N-glucosaminidase in patients with urinary tract infection. Eur Urol 1998;33:348-50.
Lockwood TD, Bosmann HB. The use of urinary N acetyl-beta-glucosaminidase in human renal toxicology I. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney. Toxicol Appl Pharmacol 1979; 49: 323-36.
Gibey R, Dupond JL, Henry JC. Urinary N-acetyl-beta D-glucosaminidase (NAG) isoenzymes profiles: a tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. Clin Chim Acta 1984; 137: 1-11.
Adiyanti SS, Loho T. Acute Kidney Injury (AKI) Biomarker. Acta Medica Indonesiana 2012;44(30:246-255.
Maisel AS, Katz N, Hillege HL, et al. Biomarkers in kidney and heart disease. Nephrol Dial Transplant 2010;1(13):doi: 10.1093/ndt/gfq647
Zhang Q, Zeng C, Cheng Z, Xie K, Zhang J, Liu Z. Primary focal segmental glomerulosclerosis in nephrotic patients: common complications and risk factors. JN Nephrol 2012;25(05):679-688.
Tamura M, Arakawa Y, Kawashima M, et al. Can early measurement of urinary n-acetyl-β-glucosaminidase help predict toxicity of cisplatin-based chemotherapy? Ann Oncol 2014;25(5): v49. doi: 10.1093/annonc/mdu435.24.
Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. International Urology and Nephrology 2014;46(1):1-7.
Katagiri d, Doi K, Honda K, Negishi K, et al. Combination of Two Urinary Biomarkers Predicts Acute Kidney Injury After Adult Cardiac Surgery. The Annals of Thoracic Surgery 2012;93(2):577–583.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney International 2008;73:1008–1016.
Bourbouze R, Bernard M, Baumann FC, Pérez-González N, Martín-Barrientos J, Cabezas JA. Subcellular distribution of N-acetyl-beta-D-glucosaminidase isoenzymes in the rabbit kidney cortex. Cell Mol Biol 1984; 30: 67-74.
Belli A, Scalercio F, Martino F, et al. Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood: Clinical study of 168 children. Minerva Pediatr 1996;48:503-7.
Cottone G, Laterza G, Amici A, et al. Effect of antibiotic chemotherapy on urinary N-acetyl-B-D-glucosaminidase activity in patients with chronic pyelonephritis. Minerva Med. 1986;77:1717-20.
Mohkam M, Karimi A, Habibian S, Sharifian M. Urinary N-Acetyl-Beta-D Glucosaminidase as a Diagnostic Marker of Acute Pyelonephritis in Children. IJKD 2008;2:24-8.
Zöller G, Wiedemann G, Kallerhoff M, Zappel H, Weber MH, Ringert RH. Mikroproteinurie und Enzymurie bei Fieber und Pyelonephritis im Kindesalter Eine prospektive Untersuchung an 180 Kindern. Der Urologe 1997;36(1):68-76.
Jantausch BA, Rifai N, Getson P, Akram S, Majd M, Wiedermann BL. Urinary N-acetyl-beta-glucosaminidase and beta-2-microglobulin in the diagnosis of urinary tract infection in febrile infants. Pediatr Infect Dis J. 1994;13:294-9.
Morita A, Numata Y, Kosugi Y, Noto A, Takeuchi N. Stabilities of N-acetyl-β-d-glucosaminidase (NAG) isoenzymes in urine: advantage of NAG isoenzyme B measurement in clinical applications. Clinica chimica acta 1998;278(1):35-43.
Williams MA, Jones D, Noe HN. Urinary n-acetyl-beta-glucosaminidase as a screening technique for vesicoureteral reflux. Urology 1994;43(4):528–530.
Miyakita H, Puri P. Urinary levels of N-acetyl-beta-D-glucosaminidase: a simple marker for predicting tubular damage in higher grades of vesicoureteric reflux. Eur Urol 1994;25:135–7.
Tomlinson PA, Smellie JM, Prescod N, Dalton RN, Chantler C. Differential excretion of urinary proteins in children with vesicoureteric reflux and reflux nephropathy. Pediatr Nephrol 1994;8:21–5.
Ohta S, Konda R, Sakai K, Kuji S, Orikasa S. Evaluation of renal function in children with primary VUR up to two years old. Nihon Hinyokika Gakkai Zasshi 1990;81(4):583-8.
Fanos V, Mussap M, Osio D, Pizzini C, Plebani M. Urinary excretion of N-acetyl-beta-D-glucosaminidase and epidermal growth factor in pediatric patients receiving cefixime prophylaxis for recurrent urinary tract infections. Clin Drug Invest 2001; 21:511–18.
Yoon JR, Koo JW. Urinary protein and enzyme excretion of spot urine in children with vesicoureteral reflux. Journal of the Korean Society of Pediatric 2009;
Goonasekera CD, Shah V, Dillon MJ. Tubular proteinuria in reflux nephropathy:post ureteric re-implanatation. Pediatr Nephrol 1996;10:559–63.
Raghad J. Ali, Firyal H. Al-Obaidi, Hala S. Arif. The Role of Urinary N-acetyl Beta-D-glucosaminidase in Children with Urological Problems. Oman Med J. 2014 Jul; 29(4): 285–288.
Carr MC, Peters CA, Retik AB, Mandell J. Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy. J Urol1994;151:442–5.
Mohkam M, Karimi A, Sharifian M, Dalirani R, Habibian S, Jadali F. Is urinary N-acetyl-beta-D-glucosaminidase a marker of urological abnormality in children? Medical Journal of the Islamic Republic of Iran 2009;23(1):36-41.
Caliskan S, Ficicioglu C, Hacibekiroglu M et al. Tubular markers in children with insulin dependent diabetes mellitus. Turk J Pediatr 1997;39:213–8.
Hsiao PH, Tsai WS, Tsai WY, Lee JS, Tsau YK, Chen CH. Urinary N-acetyl-beta- D-glucosaminidase activity in children with insulin-dependent diabetes mellitus. Am J Nephrol 1996;16:300–3.
Kato H, Takashima T, Kishikawa H, Emura S, Ohmori K. The significance of urinary N-acetyl-beta-D-glucosaminidase for predicting early stage diabetic nephropathy. Int J Clin Pract 1997;51:489–90.
Lorini R, Scaramuzza A, Cortona L, Valenti G, d’Annunzio G, Melzi d Éril GV. Increased urinary N-acetyl-beta-D-glucosaminidase excretion in young insulin-dependent diabetic patients. Diabetes Res Clin Pract 1995;29:99–105.
Basturk T, Altuntas Y, Kurklu A, Aydin L, Eren N, Unsal A. Urinary N-Acetyl B Glucosaminidase as an Earlier Marker of Diabetic Nephropathy and Influence of Low-Dose Perindopril/Indapamide Combination. Renal Failure 2006;28(2):125-128.
Csáthy L, Pócsi I. Urinary N-Acetyl-β-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Eur J Clin Chem Clin Bioch 1995;33:575–87.
Ellis EN, Brouhard BH, Lagrone L, Travis LB. Urinary Excretion of N-Acetyl-Beta-D-Glucosaminidase in Children with Type I Diabetes Mellitus. Diabetes Care 1983;6(3): 251-255.
Abdel Shakour S, El-Hefnawy H, El-Yamani MY, Azmi Y. Urinary N-acetyl-beta-D-glucosaminidase in children with diabetes as an early marker of diabetic nephropathy. East Mediterr Health J 2002;8:24–30.
Navarro JF, Mora C, Muros M, Macıéa M, Garcıéa J. Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. AJKD 2003;42(2):264–270.
Capobianco G, De Muro P, Lepedda A J, et al. Impact of first trimester fasting glycemic levels on expression of proteoglycans in pregnancy. Journal of Obstetrics and Gynaecology Research 2914; 40: 1625–1631.
Moszczynski P, Lisiewicz J. Occupational exposure to benzene, toluene and xylene and the lymphocyte lysosomal N-acetyl-beta-D-glucosaminidase. Kidney International 1986;30:804–812.
Barregård l, Hultberg B, Schütz A, Sällsten G. Enzymuria in workers exposed to inorganic mercury. International Archives of Occupational and Environmental Health 1988;61(1-2):65-69
Altunbas¸ak s, Yıldız d, Anarat A, Refik Burgut H. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatric Nephrology 2001;16(3):256-259.
Csathy L, Olah AV, Clemens B, Gyorgy I, Varga J. Urinary N-acetyl-beta-D-glucosaminidase in epileptic children treated with antiepileptic drugs. Arch Dis Child 2000;83:420–2.
Verrotti A, Greco R, Pascarella R, Matera V, Morgese G, Chiarelli F. Renal tubular function in patients receiving anticonvulsant therapy: a long-term study. Epilepsia 2000;41:1432–5.
Kos M, Jazwinska-Tarnawska E, Hurkacz M, Orzechowska-Juzwenko K, Pilecki W, Klempous J. The influence of locally implanted high doses of gentamicin on hearing and renal function of newborns treated for acute hematogenous osteomyelitis. Int J Clin Pharmacol Ther 2003;41:281–6.
Nix DE, Thomas JK, Symonds WT et al. Assessment of the enzymuria resultingfrom gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics. Ann Pharmacother 1997;31:696–70.
Olsen KM, Rudis MI, Rebuck JA et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004;32:1678–82.
Ring E, Eber E, Erwa W, Zach MS. Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child 1998;78:540–3.
Watanabe A, Nagai J, Adachi Y et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Control Release 2004;95:423–33.
Wiland P, Szechcinski J. Proximal tubule damage in patients treated with gentamicin or amikacin. Pol J Pharmacol 2003;55:631–7.
Glass S, Plant ND, Spencer DA. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis. Journal of Cystic Fibrosis 2005;4(4):221-225.
Gluhovschi G, Gadalean F, Gluhovschi C, et al. Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy. Renal Failure 2014;36(4):534-540.
Bardi E, Olah AV, Bartyik K et al. Late effects on renal glomerular and tubular function in childhood cancer survivors. Pediatr Blood Cancer 2004;43:668–73.
Zajaczkowska M, Stefaniak J, Sikora P et al. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alpha1–microglobulin in children with proliferative blood diseases. Ann Univ Mariae Curie Sklodowska [Med] 2003;58:348–53.
Higuchi H, Sumita S, Wada H et al. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity. Anesthesiology 1998;89:307–22.
Higuchi H, Adachi Y. Renal function in surgical patients after administration of low-flow sevoflurane and amikacin. J Anesth 2002;16:17–22.
Wiland P, Wiela-Hojenska A, Glowska A et al. Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab. Clin Exp Rheumatol 2004;22:469–72.
Fortes M A Q R, Andriolo A, Ortiz V, Srougi M. Effect of shock wave reapplication on urinary n-acetyl-beta-glucosaminidase in canine kidney. International Braz J Urol 2004;30(2):148-154.
Arakawa Y, Tamura M, Sakuyama T, et al. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapyn. Journal of infection and chemotherapy 2015;21(7):502–50.
Jung K, Diego J, Scholz D, Schröder K, Strobelt V. Urinary enzyme excretion by renal-transplant recipients in relation to interval after transplantation. Clinical Chemistry 1982;28(2):1762-1764.
Marchewka Z, Kuzniar J, Dlugosz A. Enzymatic markers of cyclosporine nephrotoxicity in patients after renal transplantation. Int Urol Nephrol 1999;31:727–34.
Fede C, Conti G, Chimenz R, Ricca M. N-acetyl-beta-D-glucosaminidase and beta-2–microglobulin: prognostic markers in idiopathic nephrotic syndrome. JNephrol 1999;12:51–5.
Tomlinson PA, Dalton RN, Hartley B, Haycock GB, Chantler C. Low molecular weight protein excretion in glomerular disease: a comparative analysis. Pediatr Nephrol 1997;11:285–90.
Valles P, Peralta M, Carrizo L et al. Follow-up of steroid-resistant nephrotic syndrome: tubular proteinuria and enzymuria. Pediatr Nephrol 2000;15:252–8.
Hofstra1 JM, Deegens JK, Willems HL, Wetzels JFM. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 2008;23(8):2546-2551.
Agirbasli M, Radhakrishnamurthy B, Jiang X, Bao W, Berenson GS. Urinary N-acetyl-beta-D-glucosaminidase changes in relation to age, sex, race, and diastolic and systolic blood pressure in a young adult biracial population. The Bogalusa heart study. Am J Hypertens 1996;9:157–61.
Rutkowski B, Tylicki L, Manitius J, Lysiak-Szydlowska W. Hypertensive nephropathy an increasing clinical problem. Miner Electrolyte Metab 1999;25:65–8.
Semczuk-Sikora A, Sikora P, Semczuk M. N-acetyl-beta-D-glucosaminidase activity in women with preeclampsia. Ginekol Pol 2000;71:141–5.
Semczuk-Sikora A, Sikora P, Biadun U, Semczuk M. Urinary N-acetyl-beta-D-glu cosaminidase (NAG) excretion in women with pregnancy complicated with hypertension. Ginekol Pol 2003;74:1269–75.
Tylicki L, Manitius J, Lysiak-Szydlowska W, Rutkowski B. Tubular injury: the first symptom of hypertensive kidney involvement? Med Sci Monit 2003;9:135–41.
Sterner G, Weibull H, Hultberg B, et al. Determination of urinary N-acetyl-beta-glucosaminidase in patients with hypertension and renal artery stenosis. Journal of Internal Medicine 1993; 234(3): 281–285.
Muller D, Greve D, Eggert P. Early tubular proteinuria and the development of nephritis in Henoch-Schonlein purpura. Pediatr Nephrol 2000; 15:85–9.
Zhou JH, Huang AX, Liu TL.Clinical study on treatment of childhood Henoch-Schonlein purpura nephritis with colquhounia root tablet. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:418–21.
Asami T, Nakano T, Sakai K. Renal tubular disorder in Kawasaki disease. Acta Medica Et Biologica 1989;37(3-4):125–127.
Igarashi T, Watanabe K, Inomataetal S. Renaltubular abnormalities in patients with Kawasaki disease during the acute phase. Nihon Shonika Gakkai Shi 1994;98(3).
Ohta K, Seno A, Shintani N. Increased levels of urinary interleukin-6 in Kawasaki disease. European Journal of Pediatrics 1993;152(8):647–649.
Watanabe T. Kidney and Urinary Tract Involvement in Kawasaki Disease. International Journal of Pediatrics 2013;Article ID 831834: 1-8.
Langhendries JP, Gillain N, Batiisti O, Carlier B, Bertrand JM. Normal values for urinary N-acetyl-beta-glucosaminidase excretion in preterm and term babies. Archives of Disease in Childhood 1987;62:483-486.
Willis F, Summers J, Minutillo C, Hewitt I. Indices of renal tubular function in perinatal asphyxia. Arch Dis Child Fetal Neonatal Ed 1997;77:57–60.
Tsukahara H, Hori C, Tsuchida S et al. Urinary N-acetyl-beta-D-glucosaminidase excretion in term and preterm neonates. J Pediatr Child Health 1994;30:536–8.
Dong WB, Tang ZH, Chen HY et al. Change in the level of inflammatory cytokines and their relationship to the indicator in evaluating renal tubules injury of urinary in neonates with asphyxia. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003;15:94–6.
Smolkin V, Halevy R, Levin C, et al. Renal function in children with β-thalassemia major and thalassemia intermedia. Pediatric Nephrology 2008;23(10):1847-1851.
Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with β-thalassemia major. Pediatric Nephrology 2000;15(1-2):109-112.
Jalali A, Khalilian H, Ahmadzadeh A, et al. Renal function in transfusion-dependent pediatric beta-thalassemia major patients. Hematology 2011;16(4):249-254.
Mohkam M, Shamsian S, Gharib A, Nariman S, Arzanian MT. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatric Nephrology 2008;23(6):971-976.
Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong–ajyooth S, Petrarat S, Vongjirad A. Renal tubular dysfunction in α-thalassemia. Pediatric Nephrology 2003;18(3):257-260.
Voskaridou E, Terpos E, Michail S, et al. Early markers of renal dysfunction in patients with sickle cell/ß-thalassemia. Kidney International 2006;69:2037–2042.
Kalman S, Atay AA, SakallioḠlu O. Renal tubular function in children with β-thalassemia minor. Nephrology 2005;10: 427–429.
- Abstract Viewed: 1001 times
- PDF Downloaded: 655 times